Where do we stand on neuroprotection? Where do we go from here?

Movement Disorders

Volumn 13, Issue SUPPL. 1, 1998, Pages 46-48

  Shoulson, Ira ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Clinical trials; Neuroprotection; Parkinson's disease; Positron emission tomography; Single photon emission captured tomography

Indexed keywords

ANTIOXIDANT; SELEGILINE; TOCOPHEROL;

CONFERENCE PAPER; DEGENERATIVE DISEASE; DOPAMINERGIC ACTIVITY; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIOXIDANTS; CORPUS STRIATUM; DEMENTIA; DOPAMINE; HUMANS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PROGNOSIS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031947245     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130112     Document Type: Conference Paper

References (23)

1. Greenamyre JT, Shoulson I. Huntington's disease. In Calne D, ed. Neurodegenerative diseases, Philadelphia, PA: WB Saunders, 1994:685-704.
2. Brown RH. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments. Ann Neurol 1996;39:145-146.
3. Olanow CW, Jenner P, Youdim M. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996.
4. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
5. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.
6. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol 1996;39:37-45.
7. Schulzer M, Mak E, Calne DB. The anti-Parkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798.
8. Oakes D, the Parkinson Study Group. Anti-Parkinson efficacy of deprenyl [Letter]. Ann Neurol 1993;34:634.
9. Ward CD. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994;57:217-220.
10. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681.
11. LeWitt P, Oakes D, Cui L, the Parkinson Study Group. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and a-tocopherol. Mov Disord 1997; 12:183-189.
12. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
13. Vingerhoetz FJG, Schulzer M, Calne DB, Snow BJ. Which clinical signs of Parkinson's disease best reflect the nigrostriatal lesion? Ann Neurol 1977;41:58-64.
14. Klawans HL. Individual manifestations of Parkinson's disease after ten or more years of levodopa. Mov Disord 1986;1:187-192.
15. Giladi N, McDermott, M, Fahn S, Przedborski S, the Parkinson Study Group. Freezing of gait in Parkinson's disease [Abstract]. Neurology 1996;46:A377.
16. Cummings JL. Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1988;1:245-236.
17. Rajput AM. Prevalence of dementia in Parkinson's disease. In: Huber SJ, Cummings JL, eds. Parkinson's disease: Behavioral and neuropsychological aspects. New York, NY: Oxford University Press, 1992:119-131.
18. Mindham RHS, Ahmed SAW, Clough CG. A controlled study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:969-974.
19. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992;49:492-497.
20. Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995; 52:237-245.
21. 18F-dopa positron emission tomography study. Ann Neurol 1997;41:222-229.
22. 23I] β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
23. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-145.